GeneCradle key facts
as of Oct 2026- Developer of gene therapy drugs intended to treat rare diseases.
- GeneCradle is valued at approximately $287.8M as of Oct 2026 (last reported valuation).
- It has raised $61.0M; the latest was Later Stage VC in Feb 2025.
- Notable investors include Shenzhen Capital Group, Oriental Fortune Capital, YuanBio Venture Capital, CASH Capital, Cherami Investment Group — 9 tracked in total.
- Status: Privately Held (backing).
GeneCradle's last reported valuation, Feb 2022. Nothing priced has surfaced since.
- ·Watch GeneCradle: the Monday email on marks, rounds and moves
GeneCradle funding rounds
No funding rounds for GeneCradle are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
GeneCradle valuation
GeneCradle's last reported valuation was $288 million in Feb 2022. No priced round, secondary trade or fund mark has surfaced since.
GeneCradle investors
9 investors are on record for GeneCradle, including Shenzhen Capital Group, Oriental Fortune Capital, YuanBio Venture Capital and CASH Capital. By type, the record holds 4 venture capital firms and 1 asset manager.
About GeneCradle
Developer of gene therapy drugs intended to treat rare diseases. The company's drugs are mediated by recombinant adeno-associated virus vector (rAAV) delivery technology to create new drugs in the fields of hereditary neuromuscular diseases, genetic metabolic diseases, lysosomal diseases, hereditary diseases, and ophthalmic diseases, providing healthcare professionals with a product production guarantee that meets good manufacturing practices (GMP) requirements for the development of multi-variety and multi-field genetic medicines.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2018
- Website
- bj-genecradle.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.